COMP <GO>
SBC vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
SBC Medical Group Holdings Incorporated (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: SBC 8
— ABBV 5
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: SBC
LAST: $5.69 (+4.40%) • MKT CAP: $585.2M
roic
63.10%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SBC VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SBC | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | 70.20% | +3.10 | SBC | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 63.10% | 29.00% | +34.10 | SBC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.1x | 33.3x | -27.20 | SBC | /valuation <GO> |
| Free Cash Flow Yield | 3.98% | 3.47% | +0.51 | SBC | /fcf-yield <GO> |
| Operating Margin | 38.90% | 24.60% | +14.30 | SBC | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 6.90% | +22.50 | SBC | /net-margins <GO> |
| Revenue Growth (YoY) | -15.50% | 8.60% | -24.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.46 | 5.33 | +0.13 | SBC | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.8 | 65.1 | -13.33 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 10.7x | 113.1x | -102.40 | SBC | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $585.2M | $513.86B | -$513.27B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SBC REV | ABBV REV | SBC GROSS % | ABBV GROSS % | SBC FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $173.6M | $61.16B | 73.3% | 70.2% | $23.3M | $17.82B |
| FY 2024 | $205.4M | $56.33B | 76.0% | 70.0% | $18.0M | $17.83B |
| FY 2023 | $193.5M | $54.32B | — | — | $50.7M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SBC // BETA —
ABBV // BETA 1.15